CA2842626A1 - Methods and compositions for vaccinating against staphylococcus aureus - Google Patents
Methods and compositions for vaccinating against staphylococcus aureus Download PDFInfo
- Publication number
- CA2842626A1 CA2842626A1 CA2842626A CA2842626A CA2842626A1 CA 2842626 A1 CA2842626 A1 CA 2842626A1 CA 2842626 A CA2842626 A CA 2842626A CA 2842626 A CA2842626 A CA 2842626A CA 2842626 A1 CA2842626 A1 CA 2842626A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- staphylococcus aureus
- als3p
- use according
- candida
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 14
- 229960005486 vaccine Drugs 0.000 claims abstract description 76
- 239000012634 fragment Substances 0.000 claims abstract description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 claims abstract description 41
- 230000002163 immunogen Effects 0.000 claims abstract description 33
- 241000124008 Mammalia Species 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 206010062255 Soft tissue infection Diseases 0.000 claims abstract description 17
- 238000011161 development Methods 0.000 claims abstract description 17
- 206010066409 Staphylococcal skin infection Diseases 0.000 claims abstract description 10
- 150000001413 amino acids Chemical group 0.000 claims description 36
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 10
- 241000222122 Candida albicans Species 0.000 claims description 10
- 229940095731 candida albicans Drugs 0.000 claims description 10
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 6
- 201000009906 Meningitis Diseases 0.000 claims description 6
- 101710116435 Outer membrane protein Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 6
- 229960000814 tetanus toxoid Drugs 0.000 claims description 6
- 239000000277 virosome Substances 0.000 claims description 6
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 5
- 241000222173 Candida parapsilosis Species 0.000 claims description 4
- 241000222178 Candida tropicalis Species 0.000 claims description 4
- 108010013198 Daptomycin Proteins 0.000 claims description 4
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- 241000222126 [Candida] glabrata Species 0.000 claims description 4
- 208000032343 candida glabrata infection Diseases 0.000 claims description 4
- 229940055022 candida parapsilosis Drugs 0.000 claims description 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 4
- 229960005484 daptomycin Drugs 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229960003165 vancomycin Drugs 0.000 claims description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 4
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 3
- 206010000269 abscess Diseases 0.000 description 43
- 208000015181 infectious disease Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 12
- 238000010166 immunofluorescence Methods 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 206010040872 skin infection Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229960003085 meticillin Drugs 0.000 description 7
- 208000031462 Bovine Mastitis Diseases 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 241000283074 Equus asinus Species 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- -1 alum Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 230000007233 immunological mechanism Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 101150094738 ALS3 gene Proteins 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 101000952021 Mus musculus Beta-defensin 1 Proteins 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 101000582951 Mus musculus Platelet factor 4 Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161510896P | 2011-07-22 | 2011-07-22 | |
| US61/510,896 | 2011-07-22 | ||
| PCT/US2012/000328 WO2013015831A1 (en) | 2011-07-22 | 2012-07-20 | Methods and compositions for vaccinating against staphylococcus aureus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2842626A1 true CA2842626A1 (en) | 2013-01-31 |
Family
ID=47601425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2842626A Pending CA2842626A1 (en) | 2011-07-22 | 2012-07-20 | Methods and compositions for vaccinating against staphylococcus aureus |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10653757B2 (OSRAM) |
| EP (1) | EP2734229B1 (OSRAM) |
| JP (1) | JP2014521605A (OSRAM) |
| CN (1) | CN103998056B (OSRAM) |
| AU (1) | AU2012287513A1 (OSRAM) |
| BR (1) | BR112014001409A2 (OSRAM) |
| CA (1) | CA2842626A1 (OSRAM) |
| EA (1) | EA035513B1 (OSRAM) |
| ES (1) | ES2716800T3 (OSRAM) |
| GE (1) | GEP201706766B (OSRAM) |
| UA (1) | UA114286C2 (OSRAM) |
| WO (1) | WO2013015831A1 (OSRAM) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014153241A1 (en) * | 2013-03-14 | 2014-09-25 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| WO2025240443A1 (en) * | 2024-05-14 | 2025-11-20 | University Of Rochester | Candida for use in prevention or mitigation of cutaneous viral infections |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| EP2734229B1 (en) | 2011-07-22 | 2019-01-02 | Novadigm Therapeutics, Inc. | Methods and copositions for vaccinating against staphylococcus aureus |
| EP2968501A4 (en) * | 2013-03-14 | 2017-02-15 | Rongfu Wang | Methods and compositions for modulating regulatory t cell function |
| CN105407915A (zh) * | 2013-03-15 | 2016-03-16 | 加州大学洛杉矶分校港口医学中心生物医学研究所 | 用于治疗真菌性和细菌性病原体的组合物和方法 |
| WO2017155949A1 (en) | 2016-03-09 | 2017-09-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
| CN105713096B (zh) * | 2016-03-29 | 2019-01-01 | 黑龙江八一农垦大学 | 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用 |
| AU2018379996A1 (en) | 2017-12-05 | 2020-06-25 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
| CN112203684A (zh) * | 2018-04-10 | 2021-01-08 | 海港医学中心洛杉矶生物医学研究所 | 耳念珠菌感染的治疗方法 |
| CN112940987B (zh) * | 2021-04-10 | 2022-10-14 | 福建省农业科学院畜牧兽医研究所 | 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用 |
| WO2025032534A2 (en) * | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1133829A (en) | 1978-08-24 | 1982-10-19 | Neil J.L. Gilmour | Pasteurellosis vaccines |
| US5622939A (en) | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| EP0702516A4 (en) | 1993-06-01 | 1998-04-22 | Life Technologies Inc | GENETIC IMMUNIZATION WITH CATIONIC LIPIDS |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| AU2657495A (en) | 1994-05-23 | 1995-12-18 | Research And Development Institute, Inc. | Candida albicans adhesin as a vaccine |
| US5668263A (en) | 1994-12-16 | 1997-09-16 | Smithkline Beecham Corporation | Conserved yeast nucleic acid sequences |
| ES2155129T3 (es) | 1995-06-07 | 2001-05-01 | Pfizer | Vacunacion in ovo contra la coccidiosis. |
| AU3126097A (en) | 1996-05-16 | 1997-12-05 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US7067138B1 (en) | 1999-11-19 | 2006-06-27 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US8541008B2 (en) | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
| US20060083750A1 (en) | 1999-11-19 | 2006-04-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| EP2319301B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human Ig lambda light chain genes |
| AU2003231818B2 (en) | 2002-05-21 | 2007-04-19 | Intervet International B.V. | Methods for the in vitro culture of Sporozoea sp. and user thereof |
| US7241613B1 (en) | 2002-06-05 | 2007-07-10 | Oscient Pharmaceuticals Corporation | Identification of Candida cell surface proteins and their uses |
| US7723087B2 (en) | 2002-11-12 | 2010-05-25 | The Brigham And Women's Hospital, Inc. | Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof |
| US20070141086A1 (en) * | 2003-11-21 | 2007-06-21 | Ohara Michael K | Use of antibiotics as vaccine adjuvants |
| WO2005060713A2 (en) | 2003-12-19 | 2005-07-07 | Inhibitex, Inc. | Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions |
| GB0420466D0 (en) | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
| WO2006036817A2 (en) | 2004-09-24 | 2006-04-06 | Microbia, Inc. | Fungal variants and uses thereof |
| CA2489194A1 (en) | 2004-12-03 | 2006-06-03 | Guilhem Janbon | Polypeptides involved in candida biofilm formation and uses thereof |
| WO2007126813A2 (en) | 2006-03-29 | 2007-11-08 | Inhibitex, Inc. | Cross-reactive monoclonal antibodies recognizing als family proteins |
| JP5551933B2 (ja) | 2006-04-17 | 2014-07-16 | シェーリング−プラウ・リミテッド | 組み換え弱毒化Ｃｌｏｓｔｒｉｄｉｕｍ生物体およびワクチン |
| US20080311135A1 (en) | 2007-05-22 | 2008-12-18 | Baylor College Of Medicine | Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations |
| EP2039764A1 (en) * | 2007-09-19 | 2009-03-25 | Pevion Biotech AG | Truncated secretory aspartyl proteinase 2 |
| WO2009148895A1 (en) | 2008-05-29 | 2009-12-10 | Intervet International B.V. | Coccidiosis vaccines |
| US20100150942A1 (en) | 2008-12-03 | 2010-06-17 | Cantor Thomas L | Affinity purified human polyclonal antibodies and methods of making and using them |
| SI2445522T1 (sl) * | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
| NZ597442A (en) | 2009-07-03 | 2014-01-31 | Los Angeles Biomed Res Inst | Hyr1 as a target for active and passive immunization against candida |
| WO2012163533A1 (en) | 2011-06-01 | 2012-12-06 | Eth Zurich | T cell epitope of candida albicans |
| EP2734229B1 (en) | 2011-07-22 | 2019-01-02 | Novadigm Therapeutics, Inc. | Methods and copositions for vaccinating against staphylococcus aureus |
| GB201503812D0 (en) | 2015-03-06 | 2015-04-22 | Univ Aberdeen | Antibody molecules and uses thereof |
| WO2017155949A1 (en) | 2016-03-09 | 2017-09-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
-
2012
- 2012-07-20 EP EP12817530.4A patent/EP2734229B1/en not_active Not-in-force
- 2012-07-20 BR BR112014001409A patent/BR112014001409A2/pt not_active IP Right Cessation
- 2012-07-20 JP JP2014521610A patent/JP2014521605A/ja active Pending
- 2012-07-20 US US14/234,269 patent/US10653757B2/en active Active
- 2012-07-20 ES ES12817530T patent/ES2716800T3/es active Active
- 2012-07-20 CA CA2842626A patent/CA2842626A1/en active Pending
- 2012-07-20 WO PCT/US2012/000328 patent/WO2013015831A1/en not_active Ceased
- 2012-07-20 UA UAA201310981A patent/UA114286C2/uk unknown
- 2012-07-20 GE GEAP201213225A patent/GEP201706766B/en unknown
- 2012-07-20 CN CN201280046321.4A patent/CN103998056B/zh not_active Expired - Fee Related
- 2012-07-20 EA EA201391200A patent/EA035513B1/ru not_active IP Right Cessation
- 2012-07-20 AU AU2012287513A patent/AU2012287513A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014153241A1 (en) * | 2013-03-14 | 2014-09-25 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| US11198724B2 (en) | 2013-03-14 | 2021-12-14 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| US12065485B2 (en) | 2013-03-14 | 2024-08-20 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| WO2025240443A1 (en) * | 2024-05-14 | 2025-11-20 | University Of Rochester | Candida for use in prevention or mitigation of cutaneous viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013015831A1 (en) | 2013-01-31 |
| UA114286C2 (uk) | 2017-05-25 |
| GEP201706766B (en) | 2017-10-25 |
| US20150273031A1 (en) | 2015-10-01 |
| BR112014001409A2 (pt) | 2017-07-11 |
| EP2734229A4 (en) | 2015-01-21 |
| ES2716800T3 (es) | 2019-06-17 |
| EP2734229B1 (en) | 2019-01-02 |
| AU2012287513A1 (en) | 2014-03-13 |
| US10653757B2 (en) | 2020-05-19 |
| CN103998056B (zh) | 2017-09-12 |
| EA201391200A1 (ru) | 2014-05-30 |
| EP2734229A1 (en) | 2014-05-28 |
| EA035513B1 (ru) | 2020-06-29 |
| AU2012287513A8 (en) | 2014-06-19 |
| CN103998056A (zh) | 2014-08-20 |
| JP2014521605A (ja) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10653757B2 (en) | Methods and compositions for vaccinating against Staphylococcus aureus | |
| Portuondo et al. | A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection | |
| US20190030141A1 (en) | Compositions and methods for treating fungal and bacterial pathogens | |
| JP6655549B2 (ja) | 免疫応答を誘導するための新規方法 | |
| US10160790B2 (en) | HYR1-derived compositions and methods of treatment using same | |
| US20240115693A1 (en) | Sars-cov-2 antigen nanoparticles and uses there of | |
| JP2017513849A (ja) | Ａ群レンサ球菌ワクチン | |
| Luo et al. | mRNA-based platform for preventing and treating Staphylococcus aureus by targeted staphylococcal enterotoxin B | |
| TW200911282A (en) | Pharmaceutical compound | |
| Zhao et al. | Molecular characterization and protective efficacy of a new conserved hypothetical protein of Eimeria tenella | |
| US20160030533A1 (en) | Compositions and methods of treating fungal and bacterial pathogens | |
| TW201929896A (zh) | 用於常在病原疾病進展之全面性疫苗設計 | |
| KR20190039022A (ko) | 샤가스 항원 및 항체, 및 이들의 조성물, 방법 및 용도 | |
| JP2020028219A (ja) | マラリアワクチン | |
| KR20070046096A (ko) | 다발성 경화증 치료 및 예방을 위한 방법 | |
| GB2573649A (en) | Pharmaceutical compositions and associated kits and uses | |
| Yin et al. | Immunogenicity and Protective Efficacy of Toxoplasma gondii SRS67 and SRS20A Proteins in mice | |
| US20230045642A1 (en) | S. aureus antigens and compositions thereof | |
| Smith et al. | Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect | |
| KR20230091978A (ko) | 면역원성 항원 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170720 |